1 |
Natali PG, Nicotra MR, Sures I, et al (1992b). Breast cancer is associated with loss of the c-KIT oncogene product. Int J Cancer, 52, 713-7.
DOI
|
2 |
Pan CX, Yang XJ, Lopez-Beltran A, et al (2005). c-KIT expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol, 18, 320-3.
DOI
ScienceOn
|
3 |
Pardanani A, Elliott M, Reeder T, et al (2003). Imatinib for systemic mast-cell disease. Lancet, 362, 535-6.
DOI
ScienceOn
|
4 |
Sabah M, Leader M, Kay E (2003). The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol, 11, 56-61.
|
5 |
Savage DG, Antman KH (2002). Imatinib mesylate—a new oral targeted therapy. N Engl J Med, 346, 683-93.
DOI
ScienceOn
|
6 |
Sela GB, Kuten A, ELiezer SB, Ari EG, Izhak OB (2003) expression of HER2 and c-KIT in nasopharyngeal carcinoma: Implication for a new therapeutic approach. Mod Pathol, 16, 1035-40.
DOI
ScienceOn
|
7 |
Swellam M, Abd El-Aal AA, AbuGabel Kh M (2004). Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor- expression. Clinical Biochemistry, 37, 1098-104.
DOI
ScienceOn
|
8 |
Tian Q, Frierson Jr HF, Krystal GW, et al (1999). Activating c-KIT gene mutations in human germ cell tumors. Am J Pathol, 154, 1643-7.
DOI
ScienceOn
|
9 |
Tsuura Y, Hiraki H, Watanabe K, et al (1994). preferential localization of c-KIT product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human:immunohistochemical study on formalin-fixed, paraffinembedded tissues. Virchows Arch, 424, 135-41.
|
10 |
Turner AM, Zsebo KM, Martin F, et al (1992). Nonhematopoietic tumor cell lines express stem cell factor and display c-KIT receptors. Blood, 80, 374-81.
|
11 |
Ullrich A, Schlessinger J (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-12.
DOI
ScienceOn
|
12 |
Vliagoftis H, Worobec AS, Metcalfe DD (1997). The protooncogene c-KIT and c-KIT ligand in human disease. J Allergy Clin Immunol, 100, 435-40.
DOI
ScienceOn
|
13 |
Warren W, Biggs PJ, EI-Baz M, et al (1995). Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis, 16, 1181-9.
DOI
ScienceOn
|
14 |
Went PT, Dirnhofer S, Bundi M, et al (2004). Prevalence of KIT expression in human tumors. J Clin Oncol, 22, 4514-22.
DOI
ScienceOn
|
15 |
Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002).Inhibition of KIT tyrosine kinase activity: a novel molecularapproach to the treatment of KIT-positive malignancies. JClin Oncol, 20, 1692-703.
DOI
ScienceOn
|
16 |
Yarden Y, Kuang WJ, Yang-Feng T, et al (1987). Human protooncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J, 6, 3341-51.
|
17 |
Zsebo KM, Williams DA, Geissler EN, et al (1990). Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-KIT tyrosine kinase receptor. Cell, 63, 213-24.
DOI
ScienceOn
|
18 |
Greene F, Page D, Fleming I, et al (2002). AJCC Cancer Staging Manual, 6th ed, Springer-Verlag, New York, NY,
|
19 |
Hirota S, Isozaki K, Moriyama Y, et al (1998). Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Sci, 279, 577-80.
DOI
ScienceOn
|
20 |
Holst VA, Marshall CE, Moskaluk CA, et al (1999). KIT protein expression and analysis of c-KIT gene mutation in adenoid cystic carcinoma. Mod Pathol. 12, 956-60.
|
21 |
Hornick JL, Fletcher CD (2002). Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol, 117, 188-93.
DOI
ScienceOn
|
22 |
Hsu SM, Raine L, Fanger H (1981). Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80.
DOI
ScienceOn
|
23 |
Ingram DA, Yang FC, Travers JB, et al (2000) Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med, 191, 181-8.
DOI
|
24 |
Johnson BE, Fischer T, Fischer B (2003). Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res, 9, 58807.
|
25 |
Lev S, Givol D, Yarden Y (1991). A specific combination of substrates is involved in signal transduction by the kitencoded receptor. EMBO J, 10, 647-54.
|
26 |
Kemmer K, Corless C, Fletcher C (2004). KIT mutations are common in testicular seminomas. Am J Pathol, 164, 30513.
|
27 |
Kindler T, Breitenbuecher F, Marx A (2004). The efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood, 103, 3644-54.
DOI
ScienceOn
|
28 |
Krystal GW, Hines SJ, Organ CP (1996). Autocrine growth of small cell lung cancer mediated by co-expression of c-KIT and stem cell factor. Cancer Res, 56, 370-6.
|
29 |
Lonardo F, Pass HI, Lucas DR (2003). Immunohistochemistry frequently detects c-KIT expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol, 11, 51-5.
|
30 |
Longley BJ, Reguera MJ, Ma Y (2001). Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res, 25, 571-6.
DOI
ScienceOn
|
31 |
Makhlouf HR, Remotti HE, Ishak KG (2002). Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol, 26, 493-7.
DOI
ScienceOn
|
32 |
Mokhtar N, Gouda I, Adel I (2007). Cancer pathology registry 2003-2004 and time trend analysis; Ch. 3, 24-39.
|
33 |
Mostofi FK, SobinLH, Torloni H (1973). International histological typing of urinary bladder tumors. Geneva.
|
34 |
Natali PG, Nicotra MR, Sures I, et al (1992a). Expression of c-KIT receptor in normal and transformed human nonlymphoid tissues. Cancer Res, 52, 6139-43.
|
35 |
Aydin O, Yildiz L, Kefeli M, et al (2008). CD117 expression in normal,neoplastic, inflammatory, and reactive lesions of the thyroid. Pathology Res and Practice 204: 359-65.
DOI
ScienceOn
|
36 |
Demetri GD, von Mehren M, Blanke CD, et al (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347, 472-80.
DOI
ScienceOn
|
37 |
Badr KM, Nolen JD, Derose PB, Cohen C (2004). Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). Hum Pathol. 35 184-9.
DOI
ScienceOn
|
38 |
Blume-Jensen P, Claesson-Welsh L, Siegbahn A, et al (1991). Activation of the human c-KIT product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J, 10, 4121-8.
|
39 |
Dawson B, Trapp R editors (2000). Basic and clinical biostatistics, 3rd ed. Oxford. London and Boston Lange Medical Books, 87-93.
|
40 |
DiPaola RS, Kuczynski WI, Onodera K, et al (1997). Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene, 4, 176-82.
|
41 |
Elmore LW, Domson K, Moore JR, et al (2001). Expression of c-KIT (CD117) in benign and malignant human endometrial epithelium. Arch Pathol Lab Me, 125, 146-51.
|
42 |
Gambacorti-Passerini C (2008). Part I: Milestones in personalised medicine--imatinib. Lancet Oncology, 9, 600.
DOI
ScienceOn
|